/
We are a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology ( CSN ) therapeutics. CSN therapeutics are comprised of atoms of transition elements that, when assembled in nanocrystal form, possess unusually high, unique catalytic activities not present in those same elements in bulk form.
The business is unprofitable at the operating level (-11541.50% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 41.5% YoY. Margins deteriorated 1865.2pp alongside, both lines moving the wrong way.
Negative free cash flow of -$19M. The business is consuming cash, not generating it. Operating margin contracted 1865.2pp YoY, cost discipline may be slipping.
Profitability & Returns
Revenue (TTM)
$134K
▼ -41.5% YoY
Net Income (TTM)
-$34M
▲ +33.6% YoY
Op. Margin
-15722.39%
▼ -1865.2pp YoY
ROIC
-76.78%
▼ -0.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$18M
▲ +12.9% YoY
Op. Cash Flow (TTM)
-$18M
▲ +13.0% YoY
Net Debt
$16M
Cash & Equiv.
$6M
5Y CAGR: -0.6%
Continue Research